Joshi G.Kalra S.Yadav U.P.Sharma P.Singh P.K.Amrutkar S.Ansari A.J.Kumar S.Sharon A.Sharma S.Sawant D.M.Banerjee U.C.Singh S.Kumar R.2020-02-182024-08-132020-02-182024-08-13202045206810.1016/j.bioorg.2019.103409http://10.2.3.109/handle/32116/2618In the quest to ameliorate the camptothecin (CPT) downsides, we expedite to search for stable non-CPT analogues among 11 motifs of pyrazoloquinazolines reported. E-pharmacophore drug design approach helped filtering out pyrazolo[1,5-c]quinazolines as Topoisomerase I (TopoI) 'interfacial' inhibitors. Three compounds, 3c, 3e, and 3l were shown to be potent non-intercalating inhibitors of TopoI specifically and showed cancer cell-specific cytotoxicity in lung, breast and colon cancer cell lines. The compounds induced cell cycle arrest at S-phase, mitochondrial cell death pathway and modulated oxidative stress in cancer cells. Furthermore, a preliminary study was conducted to explore the feasibility of these compounds to be developed as dual TopoI-HDAC1 (histone deacetylase 1) inhibitors (4a) to combat resistance. Compound 4a was found to possess dual inhibitory capabilities in-vitro. Cytotoxic potential of 4a was found to be significantly higher than parent compound in 2D as well as 3D cancer cell models. Probable binding modes of 4a with TopoI and HDAC1 active sites were examined by molecular modelling.en3D CultureDual inhibitorsE-pharmacophoreHistone deacetylasesPyrazolo[1,5-c]quinazolinesTopoisomerase inhibitorsArticlehttps://www.sciencedirect.com/science/article/pii/S0045206819313203